Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) — Tangible Net Worth Ratio
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has a Tangible Net Worth Ratio of 91.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥71.45 Million) from net assets (CN¥813.96 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300534 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Tangible Net Worth Ratio (2011–2025)
This chart shows how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 91.2%, reflecting net assets of CN¥813.96 Million with intangible assets of CN¥71.45 Million CNY. See operational self-sufficiency of Gansu Longshenrongfa Pharmaceutical Indu to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market value of Gansu Longshenrongfa Pharmaceutical Indu.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.9% | CN¥781.08 Million | CN¥71.46 Million | CN¥1.39 Billion | ▼ -0.5 pp |
| 2024 | 91.4% | CN¥727.93 Million | CN¥62.81 Million | CN¥1.40 Billion | ▲ +0.1 pp |
| 2023 | 91.3% | CN¥711.51 Million | CN¥62.07 Million | CN¥1.34 Billion | ▼ -1.6 pp |
| 2022 | 92.8% | CN¥763.13 Million | CN¥54.74 Million | CN¥912.79 Million | ▼ -0.2 pp |
| 2021 | 93.1% | CN¥732.84 Million | CN¥50.74 Million | CN¥824.07 Million | ▲ +0.1 pp |
| 2020 | 93.0% | CN¥739.13 Million | CN¥52.01 Million | CN¥866.66 Million | ▲ +0.0 pp |
| 2019 | 92.9% | CN¥738.88 Million | CN¥52.15 Million | CN¥810.15 Million | ▲ +0.3 pp |
| 2018 | 92.6% | CN¥720.83 Million | CN¥53.34 Million | CN¥778.51 Million | ▼ -0.8 pp |
| 2017 | 93.4% | CN¥712.19 Million | CN¥46.80 Million | CN¥782.23 Million | ▲ +0.8 pp |
| 2016 | 92.6% | CN¥703.74 Million | CN¥51.77 Million | CN¥763.48 Million | ▼ -7.0 pp |
| 2015 | 99.6% | CN¥405.57 Million | CN¥1.61 Million | CN¥646.74 Million | ▲ +0.1 pp |
| 2014 | 99.5% | CN¥363.10 Million | CN¥1.64 Million | CN¥478.49 Million | ▲ +0.1 pp |
| 2013 | 99.5% | CN¥318.92 Million | CN¥1.71 Million | CN¥453.96 Million | ▲ +0.6 pp |
| 2012 | 98.9% | CN¥171.46 Million | CN¥1.89 Million | CN¥294.53 Million | ▲ +3.0 pp |
| 2011 | 95.9% | CN¥45.35 Million | CN¥1.86 Million | CN¥120.49 Million | — |